Baicalin, a flavonoid derived from Scutellaria baicalensis, is the main metabolite of baicalein released following administration in different animal models and human. We previously reported the antiviral activity of baicalein against dengue virus (DENV). Here, we examined the anti-DENV properties of baicalin in vitro, and described the inhibitory potentials of baicalin at different steps of DENV-2 (NGC strain) replication. Our in vitro antiviral experiments showed that baicalin inhibited virus replication at IC 50 5 13.5 6 0.08 mg/ml with SI 5 21.5 following virus internalization by Vero cells. Baicalin exhibited virucidal activity against DENV-2 extracellular particles at IC 50 5 8.74 6 0.08 mg/ml and showed anti-adsorption effect with IC 50 5 18.07 6 0.2 mg/ml. Our findings showed that baicalin as the main metabolite of baicalein exerting in vitro anti-DENV activity. Further investigations on baicalein and baicalin to deduce its antiviral therapeutic effects are warranted. D engue virus (DENV) is an enveloped RNA virus belonging to the Flaviviridae family. There are four distinct serotypes, DENV-1, DENV-2, DENV-3, and DENV-4. Dengue virus can cause a range of diseases from asymptomatic infection to mild dengue fever (DF) or severe dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS) 1, 2 . DENV is transmitted principally in a cycle that involves humans and mosquito vectors, Aedes aegypti and Aedes albopictus. All DENV serotypes are widespread geographically in tropical and subtropical regions of the world, causing life-threatening disease imposing considerable health and economic burden. Currently, there is no approved vaccine or antiviral agents against clinical dengue necessitating prompt strategies to design effective antiviral strategies against this infection.
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In recent years, many investigators focus on plants and their derivatives to develop new antiviral drugs [3] [4] [5] . Some phytochemicals have been shown to have therapeutic applications against genetically and functionally diverse viruses 6, 7 . Flavonoids are polyphenolic plant metabolites with numerous biological activities and low toxicity. More than 5000 natural flavonoids have been identified in plants or various dietary sources that are presumed to have potential health benefits 8 . Antiviral properties of flavonoids, a group of plant polyphenolics have been reported against different viruses including DENVs 3, [9] [10] [11] . Recently, we showed that baicalein, a flavonoid belonging to the flavones subgroup ( Figure 1A ) exhibited significant antiviral effects against in vitro replication of DENV-2 in Vero cells, functioning at different stages of virus replication 9 . Baicalein (5, 6, 7-trihydroxyflavone) is a flavonoid originally isolated from Scutellaria baicalensis, a Chinese medicinal plant with various biological properties. Baicalin (5,6-dihydroxy-7-O-glucuronide flavone) is also a flavonoid ( Figure 1B ) presents in the roots of S.baicalensis Baicalein is metabolized and converted mainly to baicalin following intake to animals and humans [12] [13] [14] [15] [16] . It has also been shown that ,90% of baicalein administered is metabolized to baicalin 17 , and hence, it is necessary to investigate the role of baicalin in any particular medical condition.
Here, we determined the antiviral activities of baicalin at different stages of DENV replication in Vero cells and on DENV replicon cell line. We showed that baicalin interferes and inhibits DENV-2 in vitro replication at various stages of the virus replication cycle.
of baicalin was 290.9 mg/ml. At a concentration of 62.5 mg/ml, the viability of baicalin-treated Vero cells was .90% compared to vehicle control indicating that the concentration could be considered as the maximum non-toxic dose (MNTD) of baicalin for Vero cells (Figure 2) . Therefore, 50 mg/ml was chosen as the highest concentration of baicalin in all antiviral assays that was lower than the maximum non-toxic dose MNTD of baicalin.
Inhibitory effect of baicalin on BHK-DENV replicon cell line. To determine whether baicalin exerts antiviral functions at the intracellular stages of DENV-2 replication, we studied the effect of the compound on BHK-DENV subgenomic replicon cell line that encodes only non-structural viral proteins. Our results showed that baicalin inhibited replication of DENV subgenomic replicon ( Figure 3 ). Baicalin exhibited a significant antiviral activity with IC 50 5 14.9 mg/ml 6 0.07 against intracellular DENV-2 intracellular replicon by targeting non-structural protein(s) of virus. This observation corroborated the data obtained in the time-of-drugaddition studies.
Baicalin inhibits DENV-2 replication in vitro in a dose-dependent manner. The in vitro anti-DENV activity of baicalin was evaluated by DENV foci reduction assay and virus yield reduction assay. We observed that baicalin inhibited DENV-2 infectious foci in a dosedependent manner ( Figure 4A ). At 50 mg/ml of baicalin, DENV-2-induced foci formation was completely inhibited ( Figure 4C ). The antiviral effect of baicalin was further confirmed by virus yield reduction assay using q RT-PCR ( Figure 4B ). On the first day post infection the DENV RNA copy number was dropped from 609 copies (non-treated DENV infected cells) to 106 copies in the treated cells with 50 mg/ml of baicalin which is equal to 72.2% 6 0.5 inhibition of virus yield production ( Figure 4A ). Interestingly, in the second day post infection the copy number of DENV RNA in non-treated wells (15638 copies) has dropped to 1829 copies in the presence of 50 mg/ml of baicalin (78.3% 6 0.7 inhibition). The result of virus yield assay for the third day post infection showed the significant DENV replication inhibition by dropping the DENV RNA copy number from 422905 copies in the non-treated cells to 10572 copies in the treated cells with 50 mg/ml of baicalin, equal to 97.5 2% 6 0.5 DENV replication inhibition ( Figure 4C ).
Baicalin exerts virucidal activity against free DENV-2 particles.
We have previously shown that baicalein exerts significant virucidal activity against extracellular DENV-2 particles 3 . Hence, in the present study we examined whether baicalin, the main metabolite of baicalein could also inactivate extracellular DENV-2 particles and prevent subsequent infection. Baicalin was pre-incubated with the virus suspension and diluted to sub-therapeutic concentrations prior to infecting the respective host cell. Our results showed that baicalin inactivated DENV-2 virions ( Figure 5 ), and importantly, baicalin exhibited a maximum function at an IC 50 of 8.74 6 0.08 mg/ml. However, it was shown that 25 mg/ml of baicalin which was lower than MNTD of the compound was able to exhibit 96.1% 6 1 to evaluate the cytotoxicity of the baicalin. Different concentrations of baicalin up to 500 mg/ml were used to treat the Vero cells for 4 days. Data showed that the Vero cells viability after 4 days using The MNTD of baicalin is 62 mg/ml is more than 90%.Therefore, the MNTD value of baicalin is 62 mg/ml. All experiments were conducted as three independent experiments in triplicates and the data were plotted using Graph Pad Prism Version 5 (Graph Pad Software Inc., San Diego, CA.). reduction for DENV-2 infectious foci number ( Figure 5 ). The data suggested that baicalin directly inactivates free DENV-2 particles and neutralize their infectivity attributes.
Baicalin exerts inhibitory effect by acting against DENV-2 cell attachment but not entry. Next, to further characterize the antiviral mechanism(s) of baicalin, we investigated the effect of the compound against virus attachment to host cell receptors. The change in temperature between 4uC (permitting virus binding but not entry) and 37uC (facilitating virus entry/penetration) allows examination of the effect of the drug on each specific cellular event. Our study showed that baicalin prevented attachment of DENV-2 to the Vero cells ( Figure 6 ) at IC 50 5 18.07 6 0.2 mg/ml. Figure 6C showed the 75.2% 6 1.1 reduction in number of DENV foci due to interruption with DENV attachment to the cells.
To further investigate whether baicalin retained its effects against cellular penetration stage of DENV-2, we facilitated viral binding to cell receptors at 4uC followed by inactivation of unabsorbed viruses. Subsequently, the adsorbed viruses were facilitated to penetrate the host cell membrane by rendering a temperature shift to 37uC in the presence or absence of the baicalin. Our experiments did not reveal any significant activity by baicalin against penetration of attached DENV-2 to Vero cells (data not shown). Moreover, there was no significant inhibitory activity for baicalin against DENV-2 replication efficiency when it was used in pre-treatment mode (data not shown).
Antiviral activity of baicalin after virus entry to the host cell. To investigate the inhibitory effect of baicalin against intracellular DENV-2 replication, the infected Vero cells were treated with increasing concentrations of baicalin. Our investigation showed that baicalin at a concentration of 50 mg/ml inhibited DENV-2 replication to .99% ( Figure 7 ) with IC 50 5 13.50 6 0.08 mg/ml.
Discussion
Dengue virus is the most common human arbovirus with ,390 million estimated cases per year and ,96 million symptomatic patients 18 . The greatest number of dengue cases occurs in Asia and Latin America, but the disease reportedly spreads across the different unaffected parts of the world due to various factors such as climate . Anti-dengue activity of 50 mg/ml of baicalin (C); or with 25 mg/ml of baicalin (D) or without baicalin (E) using DENV foci immunostaining method on the day three post infection were shown. The respective DENV-2 RNA copy number was quantified using qRT-PCR (B). DENV-2 in vitro replication is inhibited more than 90% using 50 mg/ml of baicalin which is lower than MNTD. The percentages of foci reduction (% RF) and RNA copy number reduction were obtained by comparing against untreated controls maintained in parallel. Data from triplicate assays for three independent experiments were plotted using Graph Pad Prism Version 5 (Graph Pad Software Inc., San Diego, CA.).
www.nature.com/scientificreports SCIENTIFIC REPORTS | 4 : 5452 | DOI: 10.1038/srep05452change, increased travelling and unplanned urbanization 19 . To date, there is no licensed vaccine or effective antiviral therapy for prevention and treatment of dengue infection. Therefore, drug discovery against dengue virus remains a priority.
An efficient and safe antiviral agent for dengue virus should ideally have the potential to decrease the number of infected individuals with clinical presentations, and also protect travellers who travel to dengue endemic regions. Therefore, development of effective antidengue drug with the above mentioned criteria assumes significant priority 20 . Among the different compounds with various biological benefits including antiviral activity, flavonoids represent the target of interest to drug discovery scientists [21] [22] [23] . Baicalin, a flavonoid isolated mainly from the roots of S.baicalensis, is also the main metabolite of baicalein. In our previous study, we found that baicalein exerts antiviral activity against DENV-2 in Vero cells by different mechanisms 3 . We have also reported the anti-dengue activity of an extract of the roots of Scutellaria baicalensis as the main natural source for baicalein and baicalin against in vitro replication of dengue virus previously 24 . It was demonstrated that baicalein after administration to the different animals and human converts it to baicalin as its main metabolite 12, 13, 25 . However, the conversion of baicalin to baicalein occurs during digestion by the removal of a glycoside moiety by bglucoronidase 15, 26 . b-glucoronidase can be found as a lysosomal enzyme mainly available in the lumen of intestine and also produced by certain intestinal commensal bacteria 15, 27 but still there is no evidence related to that conversion in cell culture. Here, we report that baicalin, the main metabolite of baicalein inhibits the replication of DENV-2 in Vero cells through various mechanisms. In DENV-2 subgenomic replicon system, baicalin also showed inhibitory activity that indicates its credentials against DENV intracellular replication by potentially affecting viral genes. Our data from the replicon assay was in concordance with results of foci forming assay and virus-yield study. DENV yield in Vero cells was significantly reduced after exposing doses of baicalin lower than its MNTD.
Our studies showed that baicalin did not affect DENV replication when it was added to the Vero cells prior to virus infection. Thus, it is unlikely that it exerts antiviral activity by directly affecting the host's cell. We showed that baicalin affects DENV-2 replication when it was added after virus entry which is consistent with our previous finding on baicalein anti-dengue activity with IC 50 5 6.46 mg/ml 9 . Although, here we showed that baicalin exhibited intracellular antiviral activity against DENV-2 with IC 50 5 13.50 mg/ml its SI value however, remained 21.5, which is more significant as compared to its counterpart value for baicalein (SI 5 17.8) 9 . On the other hand, results of the virus inactivation assay suggests that baicalin could interact with extracellular DENV particles and inactivate them with SI value equal to 33.2. Accordingly, we recently showed that the extract of S.baicalensis and pure baicalein also exerted direct virucidal activity against DENV extracellular particles at SI values equal to 9.5 and 74.3, respectively 9, 24 . This property might confer baicalein and baicalin the potentials to reduce circulating DENV particles during viremic phase of the disease, which is important to minimize disease severity. Besides, it also significantly diminishes viral transmission from infected individuals to mosquitoes during blood meal.
Our data also suggest that DENV infection was significantly impaired if baicalin is present at the time of adsorption (SI 5 16). However, baicalin did not affect viral internalization following adsorption to the cell surface. These results suggest that baicalin may exert its antiviral activity by inactivation of virus particles at high concentrations and possibly by interference with DENV adsorption to Vero cells at non-virucidal concentrations. However, the precise mechanism by which baicalin inhibits the DENV binding process remains to be elucidated.
Owing to the influence made by baicalin affecting the different stages of DENV replication, further studies may be required to reveal the specific antiviral target(s) of the compound. Therefore, we currently continue our efforts to investigate the molecular and intracellular pathways the compound targets, especially especially identification of target viral genes and cellular elements such as cytokines that could play a role in facilitating its anti-DENV functions.
In conclusion, we convincingly showed that baicalin the main metabolite of baicalein, a dengue virus replication inhibitor also exerts a antiviral activity against DENV-2 in vitro replication. Baicalin interferes with intracellular virus replication besides inactivation of free DENV particles and affects viral attachment step of DENV to host cells. Insights into the precise mechanisms whereby baicalin exerts its anti-dengue activity could lead to rational designing of more effective and selective inhibitors of DENV. Our finding of antiviral properties of baicalin supports further investigations directed on anti-DENV drug development.
Methods
Cells and virus. C6/36 mosquito cells and Vero (African green monkey kidney) cells (ATCC) were cultured and maintained in Eagle's Minimum Essential Medium (EMEM, Gibco, NY, USA) supplemented with 10% fetal bovine serum (FBS) (Gibco, NY, USA). C6/36 and Vero cells were incubated at 28uC and 37uC, respectively in a 5% CO2 humidified atmosphere. BHK-DENV replicon cell line 28 was cultured and maintained in Dulbecco's Minimum Essential Medium (DMEM, Gibco, NY, USA) containing 2% FBS and 1 mg/ml G418. In this study dengue virus type-2 (DENV-2) New Guinea C strain (NGC) was used. The virus was maintained at the Virology laboratory of the Tropical Infectious Disease Research and Education Center (TIDREC), Faculty of Medicine, University of Malaya (Kuala Lumpur, Malaysia). C6/36 cells were infected with DENV-2 and supernatant consisting of viruses were harvested after observation of cytopathic effect (CPE) on day seven post infection. Virus stock to the study was prepared and titrated on Vero cells using the focus forming assay as previously described 29 and stored at 280uC until needed. At the time of virus propagation and antiviral assays, the concentration of FBS was reduced to 2%.
Flavonoid. Baicalin was purchased from Sigma Chemical Company (Sigma, St Louis, USA). The stock solution (50 mg/ml) was prepared in Dimethyl sulfoxide (DMSO) (Sigma-Aldrich, St. Louis, MO, USA) and stored at 220uC until needed. At the time of experiment, the stock solution was serially diluted using EMEM (Gibco, NY, USA), containing 2% fetal bovine serum (FBS) and sterilized with syringe filter 0.2 mm pore size (Millipore, MA, USA).
Cell cytotoxicity assay. Cytotoxicity of baicalin against Vero cells was determined using the MTT assay as previously describe 30 . Briefly, a confluent monolayer of Vero cells in 96-well cell culture microplate were treated with increasing concentrations of baicalin in triplicates for 4 days equivalent to that used in the antiviral assays. After 4 days, MTT solution (Promega, Madison, WI, USA) (15 ml) was added to each well and the microplate was kept at 37uC for 4 h in a humidified atmosphere with 5% CO 2 . Then, solubilization/stop solution (100 ml) was added to the wells and the absorbance values of the wells were measured at 570 nm using a 96-well plate reader (TECAN, Mannendorf, Switzerland). Dose-response curve was plotted using Graph Pad Prism 5 (Graph Pad Software Inc., San Diego, CA, USA, 2005) and the half maximal cytotoxic concentration (CC 50 ) of baicalin was determined from the plot. Results were represent as the means 6 standard error of the mean (SEM) from triplicate assay from three independent experiments. DENV replicon cell system. BHK-DENV replicon cells 28 were plated at a density of 1 3 10 4 cells/well in a tissue culture-treated white view 96-well plate (Promega). The following day, the all culture medium was replaced with DMEM containing of 2% FBS and increasing dilution of baicalin. Treated cells were then incubated for 48 h at 37uC in a 5% CO 2 humidified chamber. The culture medium was decaned and cells were rinsed with PBS. Cells were lysed with 100 ml of lysis buffer (Promega), and the luciferase activity was evaluated following the manufacturer's protocol (Promega). Triplicate wells were lysed at the time indicated and luminescence signal measured using the GloMAX 20/20 Luminometer (Promega). The luminescence signal was plotted against the log transformation of the concentration of baicalin and a sigmoidal curve fit with variable slope was created to obtain the half maximal inhibitory concentration (IC 50 ) value using Graph Pad Prism 5 (Graph Pad Software Inc., San Diego, CA, USA, 2005). Results were represent as the means 6 standard error of the mean (SEM) from triplicate assay from three independent experiments.
Quantitative reverse transcriptase polymerase chain reaction (qRT-PCR). Extracellular DENV-2 RNAs were extracted from the supernatant of the DENV-2 infected cells using the RNA extraction kit (Qiagen, Hilden, Germany). The quantitative RT-PCR was performed by adding 1 ml of extracted DENV-2 RNA to the SensiMix SYBR green mixture (Quantace, Watford, United Kingdom) together with www.nature.com/scientificreports 50 pmol of forward (DNF) and also reverse (D2R) primers 31 . Amplification was performed using the DNA Engine Opticon system (MJ Research/Bio-Rad, Hercules, CA) with the following thermal cycling conditions; reverse transcription at 50uC for 30 min, initial denaturation at 95uC for 10 min, followed by 45 cycles of 95uC for 15 sec, 59uC for 30 sec and 72uC for 30 sec. Melting curve analysis was subsequently performed at temperature from 60uC to 98uC to verify the assay specificity. The absolute quantities of viral RNA in the samples were measured with a standard curve generated with a 5-fold serially diluted viral RNA extracted from DENV-2 virus inoculum of known infectious titer.
Focus forming unit reduction assay (FFURA). Antiviral activity of baicalin was determined and evaluated by measuring the reduction in the number of DENV infectious foci after treatment. Briefly, infected Vero cells which were treated with different regimes were incubated for 4 days post infection (PI) using conditionedgrowth medium supplemented with 2% FBS and 1.5% carboxymethyl cellulose (CMC).Virus foci were visualized as previously described 9 . The number of DENV-2 foci was counted using a stereomicroscope and the virus titer was expressed as Foci Forming-Unit (FFU). Antiviral activities of the compounds were determined by calculating the percentage of foci reduction (%RF) compared against the controls maintained in parallel using the following formula; RF (%) 5 (C-T) 3 100/C, where, C is the mean of the number of foci from triplicates treatment without compound added (vehicle control) and T is the mean of the number of foci from triplicates of each treatment measures with the respective compound 32 . Results were represent as the means 6 standard error of the mean (SEM) from triplicate assay from three independent experiments.
Virus yield reduction assay. Vero cells were seeded in 24-well cell culture microplates. A day later, confluent monolayers were overlaid with 100 ml of EMEM containing 2% FBS together with increasing concentrations of baicalin and 100 ml of DENV-2 (NGC) suspension (moi 5 0.1). After virus adsorption, cells were washed 3 times with PBS to remove unabsorbed viruses and then the cells were further treated for 3 days with baicalin. Then the supernatant was harvested daily and the quantity of DENV RNA was determined using the real-time quantitative RT-PCR up to day 3 post infection. However, the antiviral effect of baicalin was investigated using FFURA on the day 3 post infection as well. Acyclovir (Sigma-aldrich Co, St.Louis, MO) at 1 mM was used as a non-flavivirus inhibitor throughout the period of treatment for vehicle control.
Time of addition studies. Prophylactic treatment. In order to determine the prophylactic effects of baicalin against dengue virus replication, different concentrations of baicalin were added to the confluent Vero cells in 24-wells microplate 5 hours prior to virus infection. The treatment medium was removed and the treated cells were washed twice with PBS. The cells were then infected with 200 FFU of DENV-2 and incubated at 37uC for 4 days in the presence of 5% CO 2 . After 4 days of infection, antiviral activity was determined by the reduction in foci count as previously described.
Anti-adsorption activity. The activity of baicalin against adsorption of DENV-2 to the Vero cells was measured by inoculating the confluent Vero monolayers in 24-wells cell culture microplate with 200 FFU of DENV-2 in the presence or absence of different concentrations of baicalin and incubated at 4uC for 1 hour for virus adsorption. Then the cells were washed with sterile PBS twice and overlaid with 1.5% CMC containing EMEM with 2% FBS. After 4 days of incubation, anti-adsorption activity of baicalin was determined by determining the reduction in foci numbers as described earlier.
Virus internalization inhibition. The effect of baicalin against DENV-2 internalization was investigated by adding 200 ffu of DENV-2 in triplicate to 4uC prechilled Vero cell monolayers. The microplate was incubated at 4uC for 1 h to virus attachment. After 1 h adsorption, unabsorbed viruses were removed and cells were washed with PBS and incubated at 37uC for 1 h in the presence or absence of different concentrations of baicalin. Then, cells were washed with PBS and treated with 0.1 ml of citrate buffer (Citric acid 40 mM, KCl 10 mM, NaCl 135 mM, pH 3) for 1 min to inactivate adsorbed viruses but not internalized. The cells were overlaid with maintenance medium containing 1.5% CMC and incubated at 37uC for 4 days. After 4 days of incubation, the effect of baicalin against virus internalization to the cells was determined by the reduction in foci numbers as described above.
Virus inactivation assay. A viral suspension containing 10 5 FFU of DENV-2 (MOI 5 5) incubated with equal volume of the different concentrations of baicalin for 2 h at 37uC. Then, Vero cells were infected with the 1000 fold diluted treated viral suspension in triplicates. After 1 h adsorption at 37uC, cells were washed twice with PBS. Cells were overlaid by 1.5% CMC containing EMEM with 2% FBS and incubated at 37uC for 4 days. After 4 days of incubation, direct virucidal activity of baicalin was determined by reduction in foci numbers as described earlier.
Statistical analysis. Graph Pad Prism for Windows, Version 5 (Graph Pad Software Inc., San Diego, CA, 2005) was used to determine the half maximal cytotoxic concentration (CC 50 ) and half maximal inhibitory concentration (IC 50 ) values of baicalin. All IC 50 and CC 50 values were caculated as the means 6 standard error of the mean (SEM) from triplicate assay from three independent experiments. Selectivity Index value (SI) was determined as the ratio of CC 50 to IC 50 .
